Jonathan C. Trent II MD PhD

Oncology•Miami, FL

Sarcoma

Associate Director, Clinical Research; Director, Sarcoma Program

Join to View Full Profile

1475 NW 12th AveFl 1Miami, FL 33136
Phone+1 305-243-2581
Fax+1 305-243-1293

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1995 - 1998
McGovern Medical School at UTHealthClass of 1995

Certifications & Licensure

FL State Medical License 2011 - 2026
TX State Medical License 1997 - 2013
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology
The National Board of Physicians and SurgeonsMedical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery Start of enrollment: 2005 Sep 01
Terminated
Phase 2
Ph II Study of Perifosine Plus Gleevec for Patients With GIST Start of enrollment: 2006 Aug 01
Completed
Phase 2
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST Start of enrollment: 2003 Jul 01
Completed
Phase 2
Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST) Start of enrollment: 2011 Jan 01
Withdrawn
Phase 2
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients Start of enrollment: 2013 Feb 27
Completed
Phase 1
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2017 Oct 18
Completed
Phase 1
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST Start of enrollment: 2023 Oct 17
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.
William D Tap, Gregory M Cote, Howard Burris, Lia Gore, Anthony Elias
Clinical Cancer Research. 2025-06-03
Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma.
Galina Lagos, Roman Groisberg, Andrew Elliott, Don S Dizon, Andreas Seeber
Clinical Cancer Research. 2025-06-03
Twenty-five years without progress: The enduring challenge of soft tissue sarcomas.
Nicole J Hardy, Khaoula Ben Haj Frej, Rachel Nkansah, Kelly Olino, Hari Deshpande
Cancer. 2025-06-01

Lectures

The Sarcoma Perspective in Gynecologic Oncology
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Neoadjuvant/Adjuvant Chemotherapy Should Be Considered Standard in High-Risk Extremity Soft Tissue Sarcoma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

May 2025 Sylvester Cancer Insights: Essential Tips and UpdatesMay 19th, 2025
Sylvester Cancer Tip Sheet - May 2025May 17th, 2025
Sylvester Comprehensive Cancer Center Unveils Key Insights for ASCO 2025May 1st, 2025
Join now to see all

Grant Support

Chaperonin (Sulfolobus Shibatae)National Center For Research Resources2006–2009
Activity &Resistance Of Gleevec In GI Stromal TumorsNational Cancer Institute2004–2008
Mechanism/Activity/Resistance/Gleevec/Gi Stromal Tumors (K23M)National Cancer Institute2005–2006
Chaperonins As Self-Assembling Building Blocks For NanotechnologyNational Center For Research Resources2005
Characterize Struct Of Molecular Chaperones Cytostructure Of Prokaryotic CellNational Center For Research Resources1998
Chaperonin Filaments Archaeal CytostructureNational Center For Research Resources1998

Professional Memberships

American Society of Clinical Oncology - ASCO
Member